GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ABVC BioPharma
ABVC BioPharma is a biotech company with a diversified pipeline. Its stock price is highly volatile and driven by news of clinical trials of its various drugs in areas such as oncology and neuroscience.
Share prices of companies in the market segment - Pharma other
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs based on plant extracts for the treatment of oncology, depression, and eye diseases. We have classified it in the "Other Pharma" segment. The chart below shows the overall dynamics in the sector, where natural ingredients are becoming the basis for the creation of new drugs.
Broad Market Index - GURU.Markets
ABVC BioPharma is a biopharmaceutical company with a diversified portfolio of developments in oncology, neuroscience, and ophthalmology. Its broad focus makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how ABVC compares to it.
Change in the price of a company, segment, and market as a whole per day
ABVC - Daily change in the company's share price ABVC BioPharma
For ABVC BioPharma, a company with a diversified development portfolio, daily price change is a measure of the overall volatility of its projects. This indicator reflects the market's reaction to news in various areas and is a key metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Pharma other
ABVC BioPharma, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ABVC's performance, with its diversified development portfolio, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
ABVC BioPharma is a biopharmaceutical company with a broad development pipeline, ranging from oncology to neuroscience. Its value is a composite assessment of the chances of success across multiple clinical programs. High share price volatility reflects the risks and potential of a diversified approach in biotech, contributing to the overall market momentum on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ABVC BioPharma
For ABVC BioPharma, Inc., year-over-year performance tells the story of its diversified development portfolio. Its 12-month market cap is highly volatile and depends on developments in its programs, which span oncology, neuroscience, and ophthalmology. Success in any of these areas could fundamentally alter its valuation.
Annual dynamics of market capitalization of the market segment - Pharma other
ABVC BioPharma, Inc. is a clinical-stage biotech company with a diversified portfolio. Its stock performance is entirely dependent on the results of clinical trials and partnerships. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ABVC BioPharma is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ABVC BioPharma
ABVC BioPharma is a diversified biotech company with a broad pipeline. Its monthly performance reflects news across its many clinical programs in various fields. Progress in any one of these programs can impact its overall valuation.
Monthly dynamics of market capitalization of the market segment - Pharma other
ABVC BioPharma is a biopharmaceutical company with a diversified portfolio of drugs in various stages of development for the treatment of central nervous system diseases, oncology, and ophthalmology. A chart of the pharmaceutical sector will indicate overall investor interest, but valuing ABVC requires analyzing each of its numerous, yet risky, projects.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ABVC BioPharma is a biopharmaceutical company with a broad portfolio of developments in various areas. Its diversified approach can smooth out volatility, but its stock price still depends on news about clinical trials in each area. Its correlation with the market is weak; the price reflects the sum of expectations for the entire portfolio.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ABVC BioPharma
Shares of ABVC BioPharma, an early-stage biopharmaceutical company, exhibit extreme weekly volatility. Any news, even minor, about the progress of clinical trials of its various drugs can trigger sharp and significant price movements, reflecting the high risks.
Weekly dynamics of market capitalization of the market segment - Pharma other
ABVC BioPharma shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ABVC BioPharma shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire industry. The chart shows how the company's shares react to this general "noise."
Market capitalization of the company, segment and market as a whole
ABVC - Market capitalization of the company ABVC BioPharma
ABVC BioPharma's market capitalization chart is a visualization of the high risks and potential rewards of early-stage biotech. It reflects investor hopes for a broad, yet unproven, pipeline of developments. Its highly volatile performance is a classic microcap story, where value is driven by clinical trial news rather than fundamentals.
ABVC - Share of the company's market capitalization ABVC BioPharma within the market segment - Pharma other
ABVC BioPharma is a biopharmaceutical company developing a wide range of drugs, from oncology to ophthalmology. Its sector share reflects the value of its diversified, yet early-stage, portfolio. The chart below shows how the market values its numerous research projects.
Market capitalization of the market segment - Pharma other
ABVC BioPharma is a biopharmaceutical company with a diversified development portfolio. The chart below shows the total market capitalization of the entire pharmaceutical sector. Its scale reflects global investment in healthcare. In this space, ABVC, like many small companies, is searching for a breakthrough that could change its destiny.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotech companies visible on the chart are full of risky but potentially breakthrough stories. ABVC BioPharma has a diversified development portfolio, ranging from oncology to depression treatment. Its small market cap reflects the early stage of research and the high risk inherent in this sector.
Book value capitalization of the company, segment and market as a whole
ABVC - Book value capitalization of the company ABVC BioPharma
ABVC BioPharma's book value represents capital for clinical research. While in the R&D stage, the company uses its financial assets, reflected in the chart, to develop a portfolio of drugs in oncology and neuroscience. This fuels the transformation of science into medicine.
ABVC - Share of the company's book capitalization ABVC BioPharma within the market segment - Pharma other
ABVC BioPharma, a clinical-stage biopharmaceutical company, has assets in the form of R&D capacity. Its share in the sector reflects investments in laboratories for the development of its drugs. The company's value at this stage is concentrated in its scientific portfolio, not its manufacturing facilities.
Market segment balance sheet capitalization - Pharma other
ABVC BioPharma is a clinical-stage biotech company, which means it has low capital intensity. Its value lies in its portfolio of developments and patents, not its manufacturing facilities. Compared to the entire pharmaceutical sector, which includes giants with enormous production capacities, ABVC appears very asset-light.
Book value of all companies included in the broad market index - GURU.Markets
ABVC BioPharma's assets comprise a diverse portfolio of medical developments, ranging from oncology to depression treatment. The company's balance sheet reflects the combined value of its intellectual property and clinical research. The chart shows the capital invested in this multidisciplinary scientific platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ABVC BioPharma
ABVC BioPharma is an early-stage biotech company. Its market value is largely unrelated to its book value, as investors evaluate the potential of its medical research. The chart reflects a high speculative premium for the hope of developing a successful drug, rather than for its current assets.
Market to book capitalization ratio in a market segment - Pharma other
ABVC BioPharma is a clinical-stage biotech company. Its market valuation is completely unrelated to the value of its lab equipment. This chart shows how its market capitalization, based solely on investor hopes for the success of its future drugs, far exceeds its modest book value.
Market to book capitalization ratio for the market as a whole
ABVC BioPharma is a clinical-stage biotech company. Its market capitalization reflects investor expectations for the success of its drugs' clinical trials. This chart shows the significant premium the market places on scientific potential, even when the company has virtually no tangible assets on its balance sheet.
Debts of the company, segment and market as a whole
ABVC - Company debts ABVC BioPharma
ABVC BioPharma is in the clinical stage of drug development. For biotech companies without stable revenue, debt financing is a vital resource. It helps cover the cost of years of expensive research required to obtain regulatory approval and bring drugs to market.
Market segment debts - Pharma other
ABVC BioPharma is a clinical-stage biotech company. For such companies, raising debt is rare and poses a significant risk before drug approval. This chart shows whether the company follows a standard equity financing model or uses debt, which may indicate either the maturity of its development pipeline or financial difficulties.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ABVC BioPharma
For biopharmaceutical company ABVC BioPharma, debt is a way to finance lengthy and expensive clinical trials. This chart illustrates the extent of this dependence. Every dollar of borrowed funds is a bet on successful drug approval. If the trials fail, the debt burden could become unsustainable for the company.
Market segment debt to market segment book capitalization - Pharma other
ABVC BioPharma develops drugs and medical devices with a diversified portfolio. This chart compares the company's debt raised to fund various clinical trials to the total market capitalization of the entire pharmaceutical sector. It demonstrates how the company balances risks across its numerous development projects.
Debt to book value of all companies in the market
ABVC BioPharma is focused on drug development, which requires long-term and risky investments. This chart allows investors to see how the company finances its research: through equity or debt. A comparison with the market shows whether its financial model is typical for the high-risk biotech sector.
P/E of the company, segment and market as a whole
P/E - ABVC BioPharma
This chart for ABVC BioPharma, a clinical-stage biopharmaceutical company, is a pure bet on the success of its developments. Since there is no revenue yet, any valuation is based on expectations of future drug approvals. Share price performance is not a reaction to financials, but rather a reflection of news about the progress of clinical trials and faith in scientific potential.
P/E of the market segment - Pharma other
This chart reflects the average valuation for the speculative biotech sector—the benchmark for ABVC BioPharma. The entire sector is valued based on expectations for future drugs. For investors, this benchmark reflects the overall level of optimism in the industry. This provides a useful framework for assessing expectations for ABVC's developments.
P/E of the market as a whole
ABVC BioPharma is a biotech company with a diversified development portfolio, ranging from oncology to depression treatment. Its strategy is to mitigate risk through multiple independent projects. This chart shows the overall interest in biotech. It helps us understand whether the market values the company for its diversified approach or whether its value is dependent on the success of a specific, highly promising drug.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. This chart shows analyst expectations for future clinical trial results. It illustrates the potential profit the market is pricing into the stock in anticipation of a breakthrough in research.
%20P%2FE%20ABVC%20BioPharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ABVC-BioPharma&v=1772513443068 "Chart of the company's future (projected) P/E ABVC BioPharma")
Future (projected) P/E of the market segment - Pharma other
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. This indicator compares its future profitability expectations with those of the biotech sector. This reflects investor confidence in the scientific soundness of its developments and the potential for commercialization if trials are successful.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513443095 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
ABVC BioPharma is a biotech company with a diversified pipeline of drugs. This chart shows the overall investment environment. For ABVC, whose success depends on clinical trial results rather than economics, a positive market environment is primarily important for attracting funding to continue expensive research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513443113 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. This chart illustrates the cost of medical innovation: current financial results reflect research expenses, not sales revenue.
Profit of companies in the market segment - Pharma other
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. Its future depends on the results of its trials. This chart shows the overall financial picture of the biotech sector, reflecting how successful companies are in raising capital and commercializing their research.
Overall market profit
ABVC BioPharma is a biotechnology company developing drugs and medical devices for the treatment of oncological and neurological diseases. The company has a diversified pipeline of developments at various stages. Its success depends on the results of clinical trials across multiple fronts, diversifying scientific risks.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ABVC BioPharma
ABVC BioPharma is a clinical-stage biotechnology company developing drugs to treat serious diseases. Its future depends entirely on the success of its research and regulatory approval. This graph represents a probabilistic model developed by analysts assessing the likelihood of its research projects becoming commercially successful.
%20profit%20of%20the%20company%20ABVC%20BioPharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ABVC-BioPharma&v=1772513443165 "Graph of future (projected) profit of the company ABVC BioPharma")
Future (predicted) profit of companies in the market segment - Pharma other
ABVC BioPharma is a clinical-stage biotech company with a diversified pipeline of drugs for the treatment of oncology and depression. This chart reflects the volatile expectations of the biotech sector, where future revenue is not a flat line but a series of potential breakthroughs dependent on successful clinical trial results.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513443181 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
ABVC BioPharma develops drugs and medical devices for the treatment of oncological and neurological diseases. Biotech funding is highly dependent on overall market sentiment and investor risk appetite. This graph, showing earnings forecasts, provides insight into the overall investment climate for innovative but risky projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513443191 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ABVC BioPharma
ABVC BioPharma is a clinical-stage biotechnology company developing drugs for oncology and central nervous system diseases. This chart shows how the company's valuation is net of current sales. It reflects investor expectations for successful clinical trials and the future commercial potential of its developments.
P/S market segment - Pharma other
ABVC BioPharma is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology using plant extracts. The company's valuation is based on the potential of its developments. This chart reflects industry averages, which helps understand the high expectations of investors for ABVC's pipeline.
P/S of the market as a whole
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of oncology and neurological diseases. Its valuation is based on future potential. This graph of average market revenue estimates clearly illustrates how disconnected the valuations of pioneering biotech companies are from their current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ABVC BioPharma
ABVC BioPharma is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. This chart reflects investor expectations regarding the future success of its clinical trials. The company's valuation is based on potential future drug revenues should they be approved and launched.
%20P%2FS%20ABVC%20BioPharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ABVC-BioPharma&v=1772513443246 "The graph of the company's future (projected) P/S ABVC BioPharma")
Future (projected) P/S of the market segment - Pharma other
ABVC BioPharma is a biotech company with a diversified pipeline of drugs at various stages of development. This chart compares the company's future revenue expectations with its industry. It reflects the market's combined assessment of the likelihood of success for its various clinical programs in oncology, neurology, and ophthalmology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513443270 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
ABVC BioPharma is a biopharmaceutical company developing drugs for the treatment of oncological and neurological diseases, using both Western and Eastern approaches. This chart reflects confidence in future growth, and ABVC is seeking it at the intersection of various medical traditions. The success of its developments could open new therapeutic areas and influence the sector's outlook.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513443292 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company. Its revenue, shown in this chart, is generated not from drug sales but from upfront and milestone payments under licensing agreements with partners. The dynamics reflect progress in the joint development and commercialization of its medical drugs and devices.
Sales of companies in the market segment - Pharma other
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. Every successful step in research brings the company closer to commercialization. This chart shows the total revenue of the pharmaceutical sector, which could be increased in the future by breakthrough technologies from companies like ABVC.
Overall market sales
ABVC BioPharma, a biopharmaceutical company developing drugs to treat serious diseases, is dependent on the investment climate. Periods of revenue growth, as reflected in this chart, facilitate capital inflows into the biotech sector. This allows companies like ABVC to raise the funds needed to conduct lengthy and expensive clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ABVC BioPharma
ABVC BioPharma is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. The forecast on this chart is essentially the analysts' bet on the success of its clinical trials. It shows expectations for key scientific data and potential regulatory approval of its drugs.
%20sales%20of%20the%20company%20ABVC%20BioPharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ABVC-BioPharma&v=1772513443353 "Schedule of future (projected) sales of the company ABVC BioPharma")
Future (projected) sales of companies in the market segment - Pharma other
ABVC BioPharma is a clinical-stage biotechnology company developing a pipeline of drugs for the treatment of oncology and neurological diseases. This chart shows forecasts for the entire pharmaceutical industry, allowing one to compare the risks and potential of ABVC's specific developments with overall industry trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513443380 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
For ABVC BioPharma, a company with a diversified portfolio of drugs, this chart serves as a general indicator of the state of the healthcare system. The improved economic outlook reflected here signifies greater stability in clinical research funding and the market's readiness to accept new therapeutic solutions.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513443396 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ABVC BioPharma
ABVC BioPharma is a clinical-stage biotechnology company developing drugs for oncology and central nervous system diseases. Currently, its activities are focused on research rather than sales. This metric reflects the company's investment in research and development, demonstrating how it manages capital as it works toward potential drug approval.
Market segment marginality - Pharma other
ABVC BioPharma develops drugs for the treatment of oncological and neurological diseases. In biotech, efficiency is not only about scientific breakthroughs but also about managing costs effectively during the long process of clinical trials. This chart provides an idea of how the company's operating model compares to its industry peers.
Market marginality as a whole
ABVC BioPharma is a biotech company with a diversified portfolio of drugs at various stages of development. This chart reflects average profitability, but for ABVC, the story is about managing portfolio risk. The success of even one drug in their pipeline can dramatically change their financial position and recoup all costs.
Employees in the company, segment and market as a whole
Number of employees in the company ABVC BioPharma
For biopharmaceutical company ABVC BioPharma, its headcount is its scientific and clinical engine. This chart shows the size of the team that advances a diverse pipeline of drugs through the complex stages of research and clinical trials. Team growth often signals progress in the development of new drugs.
Share of the company's employees ABVC BioPharma within the market segment - Pharma other
ABVC BioPharma is a biopharmaceutical company focused on developing new drugs. In this knowledge-intensive industry, scientists are the most important resource. The data presented shows the share of all researchers in its niche that ABVC attracts, which is a direct indicator of its scientific potential and the scale of its research programs compared to its competitors.
Number of employees in the market segment - Pharma other
ABVC BioPharma is a clinical-stage biopharmaceutical company. Its team consists primarily of scientists and clinical trial specialists. This chart shows how the company manages its resources. Headcount growth is an indicator of drug progression through the clinical trials and approaching commercialization.
Number of employees in the market as a whole
ABVC BioPharma develops drugs and medical devices. The biopharmaceutical sector often moves counter to overall economic trends, as shown in the chart. Investments in research and successful clinical trials are the primary drivers of scientist hiring, not the labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ABVC BioPharma (ABVC)
ABVC BioPharma, like many biotech companies, has a small team of scientists but holds valuable patents. This chart shows that its market capitalization is based on the potential of the drugs it develops. The sky-high per-employee ratio reflects the market's valuation of intellectual property, not production capacity.
%20of%20the%20company%20ABVC%20BioPharma%20(ABVC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ABVC-BioPharma-ABVC&v=1772513443630 "Chart of market capitalization per employee (in thousands of dollars) of the company ABVC BioPharma (ABVC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
ABVC BioPharma is a biopharmaceutical company focused on developing drugs to treat complex diseases. Here, value is created not by the number of employees, but by the quality of research and development. This metric reflects how the market assesses the potential of its R&D portfolio per scientist and employee compared to other companies in the sector.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513443664 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of central nervous system diseases and oncology. Its value lies in the potential of its scientific developments. This chart demonstrates a high market valuation per employee, typical for biotech, where the success of a single drug can generate billions in revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513443694 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ABVC BioPharma (ABVC)
ABVC BioPharma is a clinical-stage biotech company developing drugs for the treatment of central nervous system diseases and cancer. Like most R&D companies, this graph is likely to be negative. It doesn't show profit, but rather the investment (expenses) per scientist and researcher working on the development of future patented drugs.
%20Chart%20ABVC%20BioPharma%20(ABVC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ABVC-BioPharma-ABVC&v=1772513443726 "Company Profit Per Employee (in thousands of dollars) Chart ABVC BioPharma (ABVC)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
ABVC BioPharma (ABVC) is a clinical-stage biotechnology company developing drugs for the treatment of complex diseases. Like many R&D companies, its staff consists of highly qualified scientists. This chart does not reflect sales (they don't have any yet), but rather demonstrates the effectiveness of intellectual capital management. It helps understand how successfully a small team advances drug candidates through the clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513443781 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
ABVC BioPharma is a clinical-stage biotech company. It doesn't sell drugs, but rather develops them, which requires millions in R&D and testing. This chart illustrates the "biotech economics": the metric will be deeply negative while the drugs are in clinical trials. The company's entire value is in its intellectual property, and profit per employee will only emerge if a drug or partnership is approved.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513443807 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ABVC BioPharma (ABVC)
ABVC BioPharma is a biotech company working on a wide range of drugs. This graph maps their journey from lab to market. Low revenue per employee is typical for the clinical trial stage; a sharp increase would indicate commercial success for one of their drugs, developed by a small team of scientists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ABVC-BioPharma-ABVC&v=1772513443835 "Sales chart per company employee ABVC BioPharma (ABVC)")
Sales per employee in the market segment - Pharma other
ABVC BioPharma is a biotech company developing a wide range of drugs, from neuroscience to oncology. In biotech, the effectiveness of the R&D team is key to survival. This chart shows the average revenue per employee in the segment. It helps assess the productivity of ABVC's scientific platform and how it compares to other R&D companies seeking to commercialize their discoveries.
Sales per employee for the market as a whole
ABVC BioPharma is a biotech company working on a diverse portfolio of drugs, ranging from depression treatments to cancer treatments. The company is in clinical trials. This graph shows labor productivity. During the R&D phase, revenue (from grants or partnerships) per employee is typically low. This trend will change with the commercialization of the drugs.
Short shares by company, segment and market as a whole
Shares shorted by company ABVC BioPharma (ABVC)
ABVC BioPharma is a clinical-stage biopharmaceutical company with a highly diversified portfolio, ranging from depression treatments to cancer. This broad focus often raises questions. The chart shows the number of investors who doubt the resource-constrained company has the funds to bring even one of its numerous drug candidates to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ABVC-BioPharma-ABVC&v=1772513443893 "Short Shares Chart for the Company ABVC BioPharma (ABVC)")
Shares shorted by market segment - Pharma other
ABVC BioPharma is a biotech company with a broad but early-stage pipeline. This indicator measures overall skepticism in the pharmaceutical industry. When it's high, it suggests investors generally lack confidence in the success of clinical trials or anticipate funding challenges, which poses a risk to the entire early-stage industry.
Shares shorted by the overall market
ABVC BioPharma is another representative of the risky biotech sector with a broad pipeline. This chart shows the general level of fear. When pessimism increases, investors are unwilling to delve into the nuances of R&D. They see a company without stable revenue and sell it, fearing that the funds for research will run out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ABVC BioPharma (ABVC)
This oscillator shows the high volatility of ABVC BioPharma. The company has a highly diversified portfolio, ranging from cancer and depression treatments to eye medications. This breadth means news could come from any direction. Success in one of the many trials pushes the indicator into overbought territory (above 70). A failure in another—or the need to raise capital—instantly drops it below 30.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ABVC-BioPharma-ABVC&v=1772513443948 "RSI 14 indicator chart for the company's stock ABVC BioPharma (ABVC)")
RSI 14 Market Segment - Pharma other
ABVC BioPharma (ABVC) is a diversified biotech. They have a "basket" of diverse projects, from Alzheimer's to oncology. The "other pharma" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is ABVC's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
ABVC BioPharma (ABVC) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ABVC (ABVC BioPharma)
ABVC BioPharma is a biotech company with a diversified R&D portfolio, including drugs for the treatment of central nervous system disorders (depression) and ophthalmology. This chart shows the speculative average target price from analysts, reflecting their assessment of this broad but risky pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ABVC-ABVC-BioPharma&v=1772513444052 "A chart showing analyst consensus forecasts for the expected stock price. ABVC (ABVC BioPharma)")
The difference between the consensus estimate and the actual stock price ABVC (ABVC BioPharma)
ABVC BioPharma (ABVC) is a biotech "lottery" with a diversified (but early) pipeline, from Alzheimer's to oncology. This chart is a barometer of their R&D. It measures the vast gap between the speculative price and the consensus target, reflecting whether analysts believe (or even believe) in any of their many projects.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ABVC-ABVC-BioPharma&v=1772513444087 "A chart showing the difference between the consensus forecast and the actual stock price. ABVC (ABVC BioPharma)")
Analyst consensus forecast for stock prices by market segment - Pharma other
ABVC BioPharma is a biotech company developing a wide range of drugs, from eye care to oncology and treatments for central nervous system disorders. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe a company with such a broad portfolio can successfully deliver on its R&D goals.
Analysts' consensus forecast for the overall market share price
ABVC BioPharma is a Taiwanese biotech company developing a wide range of drugs, from central nervous system medications to eye treatments. This chart shows the company's overall risk appetite. For ABVC, a company with a highly diversified and risky portfolio, overall market optimism (risk appetite) is critical to raising capital to fund all of its projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ABVC BioPharma
ABVC BioPharma is a clinical-stage biotech with a diversified R&D pipeline spanning neurology (ADHD), ophthalmology, and oncology. This chart is a summary indicator of their R&D pipeline. It reflects the market's speculative valuation of their (very diverse) clinical programs and their ability to fund this diverse approach.
AKIMA Market Segment Index - Pharma other
ABVC BioPharma (ABVC) is a biopharmaceutical company developing a wide range of drugs, from central nervous system medications to oncology and ophthalmology, often using plant extracts. The chart shows the average index for the segment, allowing investors to assess how this diversified yet risky development portfolio compares to the pharmaceutical industry average.
The AKIM Index for the overall market
ABVC BioPharma is a biopharmaceutical company developing drugs and medical devices, often based on traditional Chinese medicine. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this niche R&D company fits within the context of overall economic trends in healthcare.
